POPULARITY
12 episodes with alectinib
12 episodes with alectinib
2 episodes with alectinib
2 episodes with alectinib
In episode 81 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Betsy Beggs of Goldman Sachs. At 23 years old, Betsy was a young professional finding her footing in New York City when she was blindsided by a stage 4 ALK+ lung cancer diagnosis. Tune in as she bravely shares her cancer story. For more, listen to Sarah Beggs, Betsy's mother, share her story from a parent perspective: youtu.be/05CrU4ltf80
In this episode, hosts Drs. Rahul and Rohit Gosain are joined by special guest Dr. Joshua Sabari, a thoracic medical oncologist from NYU Langone Health. Together, they dive into the highlights from ASCO 2024, focusing on key studies in lung cancer. Here's a quick summary of what you can expect in this episode: • LAURA Trial: Discussing the use of Osimertinib as a consolidation approach after chemoradiation in unresectable stage 3 non-small cell lung cancer patients with common EGFR mutation. • MARIPOSA Study: Exploring the potential of Amivantamab and Lazertinib in common EGFR mutations. • CROWN Study and other ALK inhibitors: Alectinib, Lorlatinib, and Brigatinib for metastatic non-small cell lung cancer. • ADRIATIC Study: Examining the use of Durvalumab after concurrent chemoradiation in limited-stage small cell lung cancer. • PALOMA-3 Trial: Discussing subcutaneous Amivantamab vs. IV Amivantamab with Lazertinib Join the Oncology Brothers and Dr. Sabari as they break down these practice-changing studies and provide insights into the latest advancements in lung cancer treatment. Don't miss out on this informative and engaging discussion! Stay tuned for more ASCO 2024 highlights and updates on GI, GU, and breast cancer in the upcoming episodes. Subscribe to the Oncology Brothers Podcast for the latest in oncology news and research. Thank you for listening! Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.
Dennis Wigle and Linda Martin from Mayo Clinic and University of Virginia, respectively, discuss recent trials from the meeting of the European Society for Medical Oncology (ESMO), particularly highlighting the ALINA trial focusing on adjuvant treatments for resected non small cell lung cancers with impressive differences in outcomes between Alectinib and platinum-based chemotherapy. In addition, they provide a review of multiple perioperative immunotherapy trials from 2023 and share their hopes for the field in 2024. This podcast is sponsored by Genentech.
In discussion with Dr. Joshua Reuss, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Reuss: - Keynote 671 – perioperative approach in non-small cell lung cancer with pembrolizumab and cisplatin based chemo combination, with positive OS data - ALINA – resectable non-small cell lung cancer pts with ALK positive disease, Alectinib will be the new standard of care given incredible DFS - TropionLung 01 – Dato-DXd in 2nd line non-small cell lung cancer reports slightly greater PFS when compared to docetaxel #ESMO #PrecisionMedicine #LungCancer #2023 #cancer #oncology #oncbrothers
In this episode, Michael and Josh step onto the oncological Nautilus, to begin their journey 20,000 Leagues Under Lung Cancer, to examine non-small cell lung cancer with mutations other than EGFR. The first step on their journey is discussing the anaplastic lymphoma kinase, a tyrosine kinase inhibitor associated with the development of non-small cell lung cancer in younger patients who have never smoked. Thankfully, unlike their previous episode, there are treatment options galore for patients with ALKmut NSCLC. Two of the contenders for the title of "The King of the ALK" are alectinib and lorlatinib. Alectinib has more robust overall survival data, but lorlatinib has hazard ratios so ridiculously good that they would almost meet statistical significance as p values! So which is better? Listen on to find out.Links to studies discussed in this episode (subscription may be required):ALEX: https://www.nejm.org/doi/full/10.1056/nejmoa1704795CROWN: https://www.nejm.org/doi/full/10.1056/NEJMoa2027187For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.
Commentary by Dr. Lavanya Kondapalli
Lung Pod - condivisione di esperienze cliniche in ambito lung cancerUna rassegna di casi clinici e di esperienze sul campo riguardanti la diagnosi, la gestione e il trattamento delle neoplasie polmonari nel setting real world in questi podcast che vedono protagonisti alcuni dei più importanti esperti italiani.Seguici sui nostri socialInstagram (@drtalk_it)Twitter (@drtalk_it)YouTube (DrTalk_it)
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Dr. Caroline McCoach discusses What are the options after a patient with an ALK-positive advanced NSCLC develops resistance on Alecensa-alectinib
MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry …Mohammad Jahanzeb AJ0
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, Monsanto, Bayer, Leo Pharma, GSK, 23andMe.Persone: Rolf Ackermann (Monsanto), Heiko Schipper (Bayer), Arianna Bellucci (Università di Brescia).Nuove terapie: Alectinib, Dinutuximab Beta.Patologie: Tumore al polmone non a piccole cellule, Neuroblastoma, Diabete di tipo 1, Morbo di Parkinson, Cardiopatia Ischemica, Corea di Huntington.Lavoro: Global Pharmacovigilance Specialist, Medical Science Liaison, Clinical Research Associate.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, Monsanto, Bayer, Leo Pharma, GSK, 23andMe.Persone: Rolf Ackermann (Monsanto), Heiko Schipper (Bayer), Arianna Bellucci (Università di Brescia).Nuove terapie: Alectinib, Dinutuximab Beta.Patologie: Tumore al polmone non a piccole cellule, Neuroblastoma, Diabete di tipo 1, Morbo di Parkinson, Cardiopatia Ischemica, Corea di Huntington.Lavoro: Global Pharmacovigilance Specialist, Medical Science Liaison, Clinical Research Associate.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/
Dr Shaw speaks with ecancer at ASCO 2017 about results from the ALEX trial of alectinib, a next-generation ALK inhibitor, for patients with lung cancer containing ALK mutations. She describes the significant benefits of alectinib over crizotinib, with progression free survival at 25.7 months compared to 10.4 months, fewer side effects and a reduced incidence of brain metastases. Overall, Dr Shaw encourages the use of alectinib as the new standard of care, and for doctors to discuss its use with patients currently receiving crizotinib.
Dr Shaw presents, at a press conference at ASCO 2017, findings from a phase III clinical trial that point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer.
Podcast re: 'Three-year Follow-up of an Alectinib Phase 1/2 Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP' by Tamura et al.
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.
Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
Today in FirstWord:
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.
Several new treatments for ALK positive lung cancer patients are on the horizon. In this video, the doctors discuss them while patients in the audience share some of their experiences with side effects on various treatments.
Several new treatments for ALK positive lung cancer patients are on the horizon. In this video, the doctors discuss them while patients in the audience share some of their experiences with side effects on various treatments.
Several new treatments for ALK positive lung cancer patients are on the horizon. In this video, the doctors discuss them while patients in the audience share some of their experiences with side effects on various treatments.
© 2020-2025 Ivy Podcast Discovery LLC
